Europe
Keppra® is indicated in Europe as:
- monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy
- adjunctive therapy for partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy
- adjunctive therapy for myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy (JME)
- adjunctive therapy for the treatment of Primary Generalised Tonic-Clonic (PGTC) seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy (IGE).
In Europe, Keppra® is also available as 100 mg/mL concentrate for solution for infusion and is indicated as:
- monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy
- adjunctive therapy for partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy
- adjunctive therapy for myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy (JME)
- adjunctive therapy for the treatment of Primary Generalised Tonic-Clonic (PGTC) seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy (IGE).
Keppra concentrate is an alternative for patients when oral administration is temporarily not feasible.